{"relation": [["", "Placebo \u2192 Glimepiride 2 mg \u2192 Glimepiride 4 mg", "Glimepiride 2 mg \u2192 Glimepiride 4 mg \u2192 Placebo", "Glimepiride 4 mg \u2192 Placebo \u2192 Glimepiride 2 mg", "Placebo \u2192 Glimepiride 4 mg \u2192 Glimepiride 2 mg", "Glimepiride 2 mg \u2192 Placebo \u2192 Glimepiride 4 mg", "Glimepiride 4 mg \u2192 Glimepiride 2 mg \u2192 Placebo"], ["Description", "Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.", "Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.", "Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.", "Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.", "Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.", "Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period."]], "pageTitle": "Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253) - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT01614769?sect=X0125&view=results", "hasHeader": true, "headerPosition": "MIXED", "tableType": "RELATION", "tableNum": 3, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989042.37/warc/CC-MAIN-20150728002309-00037-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 876922944, "recordOffset": 876906550, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Placebo Drug: Glimepiride 2 mg Drug: Glimepiride 4 mg Procedure: Hypoglycemic Clamp Interventions: Type 2 Diabetes Mellitus Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Crossover\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Investigator); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: January 2, 2014 \u00a0", "textAfterTable": "Participant Flow for 5 periods Period 1: \u00a0 Period 1 \u00a0 \u00a0 Placebo \u2192 Glimepiride 2 mg \u2192 Glimepiride 4 mg \u00a0 \u00a0 Glimepiride 2 mg \u2192 Glimepiride 4 mg \u2192 Placebo \u00a0 \u00a0 Glimepiride 4 mg \u2192 Placebo \u2192 Glimepiride 2 mg \u00a0 \u00a0 Placebo \u2192 Glimepiride 4 mg \u2192 Glimepiride 2 mg \u00a0 \u00a0 Glimepiride 2 mg \u2192 Placebo \u2192 Glimepiride 4 mg \u00a0 \u00a0 Glimepiride 4 mg \u2192 Glimepiride 2 mg \u2192 Placebo \u00a0 STARTED \u00a0 \u00a0 2 \u00a0 \u00a0 1 \u00a0 \u00a0 2 \u00a0 \u00a0 2 \u00a0 \u00a0 1 \u00a0 \u00a0 2 \u00a0 COMPLETED \u00a0 \u00a0 1 \u00a0 \u00a0 1 \u00a0 \u00a0 2 \u00a0 \u00a0 0 \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}